Clinical Trial

Ambulatory Stroke Unit Treatment for Elderly Patients

Study acronym: ARTIFICE
Recruiting
View on ClinicalTrials.gov →
Summary
ARTIFICE is a prospective, multicenter, randomized, controlled, exploratory non-inferiority trial evaluating whether an ambulatory stroke unit model (aSU) is non-inferior to conventional inpatient stroke unit care (SU) in patients aged 60 years or older with acute ischemic stroke, transient ischemic attack (TIA), or retinal ischemia and non-disabling neurological deficits. Eligible patients are randomized 1:1 to same-day comprehensive ambulatory multiprofessional stroke evaluation (aSU) or guideline-based inpatient stroke unit treatment (SU). The primary endpoint is favorable functional outcome at 90 days, defined as modified Rankin Scale (mRS) 0-2 or return to pre-stroke mRS. Endpoint assessment at 90 days is performed by blinded assessors (PROBE design). Secondary outcomes include early neurological deterioration, recurrent stroke, delirium, mortality, health-related quality of life, healthcare utilization, and cost-effectiveness. A mixed-methods process evaluation examines feasibility, acceptability, and implementation aspects of the ambulatory care model.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-01
Trial Details
NCT Number NCT07420374
Lead Sponsor University Hospital Heidelberg
Collaborators: Heinrich-Heine University, Duesseldorf, inav - Institute for Applied Health Services Research GmbH, Berlin, Germany
Conditions Ischemic Stroke, Transient Ischemic Attack (TIA), Retinal Ischemia
Enrollment 400 participants
Start Date 2026-03-25
Primary Completion 2028-09 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-31